- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01810913
Tester le docétaxel-cétuximab ou l'ajout d'un médicament d'immunothérapie, l'atezolizumab, à la chimiothérapie et à la radiothérapie habituelles dans le cancer de la tête et du cou à haut risque
Essai randomisé de phase II/III sur la radiothérapie adjuvante avec le cisplatine, le docétaxel-cétuximab ou le cisplatine-atezolizumab dans le cancer épidermoïde pathologique à haut risque de la tête et du cou
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Aperçu de l'étude
Statut
Les conditions
- Carcinome épidermoïde hypopharyngé de stade IV AJCC v7
- Carcinome épidermoïde laryngé de stade IV AJCC v7
- Carcinome épidermoïde de la cavité buccale de stade IV AJCC v6 et v7
- Carcinome épidermoïde oropharyngé de stade IV AJCC v7
- Carcinome épidermoïde négatif oropharyngé p16INK4a
- Carcinome épidermoïde hypopharyngé de stade III AJCC v7
- Carcinome épidermoïde laryngé de stade III AJCC v6 et v7
- Carcinome épidermoïde de la cavité buccale de stade III AJCC v6 et v7
- Carcinome épidermoïde oropharyngé de stade III AJCC v7
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To select the better docetaxel-based experimental arm to improve disease-free survival (DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF 20-MAR-2020) II. To determine if the combination of docetaxel-cetuximab and intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). (Phase III) III. To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC. (Phase III)
SECONDARY OBJECTIVES:
I. To compare disease-free survival (DFS) between each experimental arm and the control arm. (Phase III) II. To determine whether each experimental arm improves local-regional disease control and the rate of distant metastasis. (Phase III) III. To compare acute toxicity profiles between each experimental arm and the control arm. (Phase III) IV. To compare late toxicity profiles at 1, 3, and 5 years after treatment. (Phase III) V. To assess long term DFS and OS between each experimental arm and the control arm. (Phase III) VI. To compare symptom burden, as measured by the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) (primary patient reported outcome [PRO]), and quality of life, as measured by the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) (secondary PRO), between each experimental arm and the control arm. (Phase III)
EXPLORATORY OBJECTIVE:
I. To collect blood and tissue specimens for future translational research. (Phase III)
OUTLINE: Patients are randomized to 1 of 3 arms - Phase II (Arms 1, 2 or 3) and for Phase III (Arms 1, 3 or 4).
ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) five days a week for 6 weeks and receive concurrent cisplatin intravenously (IV) over 1-2 hours once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. (CLOSED AS OF 20-MAR-2020)
ARM 3: Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and concurrently receive docetaxel once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
ARM 4: Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity.
All patients undergo collection of blood samples during screening and throughout the study and may undergo computed tomography (CT) scans and/or magnetic resonance imaging (MRI) and biopsy as clinically indicated on study.
After completion of study treatment, patients are followed up at 1 and 3 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
Shatin, Hong Kong
- Chinese University of Hong Kong-Prince of Wales Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham, Alabama, États-Unis, 35243
- The Kirklin Clinic at Acton Road
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, États-Unis, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, États-Unis, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Burbank, California, États-Unis, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Cameron Park, California, États-Unis, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Carmichael, California, États-Unis, 95608
- Mercy San Juan Medical Center
-
Encinitas, California, États-Unis, 92024
- UC San Diego Health System - Encinitas
-
La Jolla, California, États-Unis, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, États-Unis, 90048
- Cedars-Sinai Medical Center
-
Modesto, California, États-Unis, 95355
- Memorial Medical Center
-
Orange, California, États-Unis, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, États-Unis, 94304
- Stanford Cancer Institute Palo Alto
-
Roseville, California, États-Unis, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Sacramento, California, États-Unis, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, États-Unis, 95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, États-Unis, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, États-Unis, 94115
- UCSF Medical Center-Mount Zion
-
San Mateo, California, États-Unis, 94401
- Mills Health Center
-
St. Helena, California, États-Unis, 94574
- Saint Helena Hospital
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, États-Unis, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, États-Unis, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, États-Unis, 80210
- AdventHealth Porter
-
Edwards, Colorado, États-Unis, 81632
- Shaw Cancer Center
-
Greeley, Colorado, États-Unis, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, États-Unis, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Longmont, Colorado, États-Unis, 80501
- Longmont United Hospital
-
Loveland, Colorado, États-Unis, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, États-Unis, 80138
- AdventHealth Parker
-
-
Connecticut
-
Farmington, Connecticut, États-Unis, 06030
- University of Connecticut
-
New Haven, Connecticut, États-Unis, 06520
- Yale University
-
Waterford, Connecticut, États-Unis, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark, Delaware, États-Unis, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, États-Unis, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20037
- George Washington University Medical Center
-
-
Florida
-
Deerfield Beach, Florida, États-Unis, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale, Florida, États-Unis, 33308
- Holy Cross Hospital
-
Miami, Florida, États-Unis, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, États-Unis, 32806
- Orlando Health Cancer Institute
-
Orlando, Florida, États-Unis, 32803
- AdventHealth Orlando
-
Ruskin, Florida, États-Unis, 33570
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, États-Unis, 33612
- Moffitt Cancer Center
-
Tampa, Florida, États-Unis, 33607
- Moffitt Cancer Center-International Plaza
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, États-Unis, 30322
- Emory University Hospital/Winship Cancer Institute
-
Augusta, Georgia, États-Unis, 30912
- Augusta University Medical Center
-
Savannah, Georgia, États-Unis, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, États-Unis, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, États-Unis, 96817
- The Cancer Center of Hawaii-Liliha
-
-
Idaho
-
Nampa, Idaho, États-Unis, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
Chicago, Illinois, États-Unis, 60612
- University of Illinois
-
Chicago, Illinois, États-Unis, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, États-Unis, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, États-Unis, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, États-Unis, 62401
- Crossroads Cancer Center
-
Evanston, Illinois, États-Unis, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Glenview, Illinois, États-Unis, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, États-Unis, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
O'Fallon, Illinois, États-Unis, 62269
- HSHS Saint Elizabeth's Hospital
-
Oak Lawn, Illinois, États-Unis, 60453-2699
- Advocate Christ Medical Center
-
Peoria, Illinois, États-Unis, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, États-Unis, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Rockford, Illinois, États-Unis, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, États-Unis, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, États-Unis, 61801
- Carle Cancer Center
-
-
Indiana
-
Anderson, Indiana, États-Unis, 46016
- Ascension Saint Vincent Anderson
-
Elkhart, Indiana, États-Unis, 46515
- Elkhart General Hospital
-
Fort Wayne, Indiana, États-Unis, 46805
- Parkview Hospital Randallia
-
Fort Wayne, Indiana, États-Unis, 46845
- Parkview Regional Medical Center
-
Fort Wayne, Indiana, États-Unis, 46804
- Radiation Oncology Associates PC
-
Goshen, Indiana, États-Unis, 46526
- Goshen Center for Cancer Care
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, États-Unis, 46219
- IU Health Central Indiana Cancer Centers-East
-
Indianapolis, Indiana, États-Unis, 46202
- IU Health Methodist Hospital
-
Mishawaka, Indiana, États-Unis, 46545
- Michiana Hematology Oncology PC-Mishawaka
-
South Bend, Indiana, États-Unis, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- McFarland Clinic - Ames
-
Des Moines, Iowa, États-Unis, 50309
- Iowa Methodist Medical Center
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas Cancer Center
-
Lawrence, Kansas, États-Unis, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, États-Unis, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, États-Unis, 66210
- University of Kansas Cancer Center-Overland Park
-
Salina, Kansas, États-Unis, 67401
- Salina Regional Health Center
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, États-Unis, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
Louisville, Kentucky, États-Unis, 40245
- UofL Health Medical Center Northeast
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, États-Unis, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, États-Unis, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, États-Unis, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, États-Unis, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, États-Unis, 70115
- Touro Infirmary
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, États-Unis, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, États-Unis, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, États-Unis, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, États-Unis, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
Silver Spring, Maryland, États-Unis, 20910
- Holy Cross Hospital
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02118
- Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, États-Unis, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, États-Unis, 48116
- University of Michigan - Brighton Center for Specialty Care
-
Brighton, Michigan, États-Unis, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, États-Unis, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, États-Unis, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, États-Unis, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
Grand Rapids, Michigan, États-Unis, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, États-Unis, 49201
- Allegiance Health
-
Kalamazoo, Michigan, États-Unis, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, États-Unis, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, États-Unis, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Novi, Michigan, États-Unis, 48377
- Henry Ford Medical Center-Columbus
-
Royal Oak, Michigan, États-Unis, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, États-Unis, 48601
- MyMichigan Medical Center Saginaw
-
Troy, Michigan, États-Unis, 48085
- Corewell Health Beaumont Troy Hospital
-
West Bloomfield, Michigan, États-Unis, 48322
- Henry Ford West Bloomfield Hospital
-
Wyandotte, Michigan, États-Unis, 48192
- Henry Ford Wyandotte Hospital
-
Wyoming, Michigan, États-Unis, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Bemidji, Minnesota, États-Unis, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, États-Unis, 55337
- Minnesota Oncology - Burnsville
-
Duluth, Minnesota, États-Unis, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, États-Unis, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, États-Unis, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic in Rochester
-
Saint Cloud, Minnesota, États-Unis, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, États-Unis, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, États-Unis, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Columbia, Missouri, États-Unis, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Creve Coeur, Missouri, États-Unis, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, États-Unis, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, États-Unis, 64116
- North Kansas City Hospital
-
Kansas City, Missouri, États-Unis, 64131
- The University of Kansas Cancer Center-South
-
Lee's Summit, Missouri, États-Unis, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Rolla, Missouri, États-Unis, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, États-Unis, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, États-Unis, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
St Louis, Missouri, États-Unis, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, États-Unis, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, États-Unis, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Kearney, Nebraska, États-Unis, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, États-Unis, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, États-Unis, 68124
- Alegent Health Bergan Mercy Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Memorial Sloan Kettering Basking Ridge
-
Hamilton, New Jersey, États-Unis, 08690
- The Cancer Institute of New Jersey Hamilton
-
Livingston, New Jersey, États-Unis, 07039
- Cooperman Barnabas Medical Center
-
Long Branch, New Jersey, États-Unis, 07740
- Monmouth Medical Center
-
Middletown, New Jersey, États-Unis, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, États-Unis, 07645
- Memorial Sloan Kettering Bergen
-
Mount Holly, New Jersey, États-Unis, 08060
- Virtua Memorial
-
New Brunswick, New Jersey, États-Unis, 08903
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, États-Unis, 07101
- Rutgers New Jersey Medical School
-
Somerville, New Jersey, États-Unis, 08876
- Robert Wood Johnson University Hospital Somerset
-
Sparta, New Jersey, États-Unis, 07871
- Sparta Cancer Treatment Center
-
Toms River, New Jersey, États-Unis, 08755
- Community Medical Center
-
Voorhees Township, New Jersey, États-Unis, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, États-Unis, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Bay Shore, New York, États-Unis, 11706
- South Shore University Hospital
-
Brooklyn, New York, États-Unis, 11215
- New York-Presbyterian/Brooklyn Methodist Hospital
-
Brooklyn, New York, États-Unis, 11220
- NYU Langone Hospital - Brooklyn
-
Buffalo, New York, États-Unis, 14263
- Roswell Park Cancer Institute
-
Canandaigua, New York, États-Unis, 14424
- Sands Cancer Center
-
Commack, New York, États-Unis, 11725
- Memorial Sloan Kettering Commack
-
Elmira, New York, États-Unis, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Harrison, New York, États-Unis, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, États-Unis, 11042
- Northwell Health/Center for Advanced Medicine
-
Mineola, New York, États-Unis, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, États-Unis, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, États-Unis, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
New York, New York, États-Unis, 10003
- Mount Sinai Union Square
-
Rochester, New York, États-Unis, 14642
- University of Rochester
-
Rochester, New York, États-Unis, 14620
- Highland Hospital
-
Rochester, New York, États-Unis, 14606
- Wilmot Cancer Institute Radiation Oncology at Greece
-
Sleepy Hollow, New York, États-Unis, 10591
- Memorial Sloan Kettering Sleepy Hollow
-
Syracuse, New York, États-Unis, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, États-Unis, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, États-Unis, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, États-Unis, 11553
- Memorial Sloan Kettering Nassau
-
-
North Carolina
-
Albemarle, North Carolina, États-Unis, 28002
- Atrium Health Stanly/LCI-Albemarle
-
Chapel Hill, North Carolina, États-Unis, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, États-Unis, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, États-Unis, 28210
- Atrium Health Pineville/LCI-Pineville
-
Charlotte, North Carolina, États-Unis, 28262
- Atrium Health University City/LCI-University
-
Concord, North Carolina, États-Unis, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Greenville, North Carolina, États-Unis, 27834
- East Carolina University
-
Kinston, North Carolina, États-Unis, 28501
- ECU Health Oncology Kinston
-
Monroe, North Carolina, États-Unis, 28112
- Atrium Health Union/LCI-Union
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, États-Unis, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, États-Unis, 58122
- Sanford Roger Maris Cancer Center
-
-
Ohio
-
Akron, Ohio, États-Unis, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, États-Unis, 44304
- Summa Health System - Akron Campus
-
Avon, Ohio, États-Unis, 44011
- UH Seidman Cancer Center at UH Avon Health Center
-
Barberton, Ohio, États-Unis, 44203
- Summa Health System - Barberton Campus
-
Beachwood, Ohio, États-Unis, 44122
- UHHS-Chagrin Highlands Medical Center
-
Chardon, Ohio, États-Unis, 44024
- Geauga Hospital
-
Chillicothe, Ohio, États-Unis, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, États-Unis, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, États-Unis, 44106
- Case Western Reserve University
-
Cleveland, Ohio, États-Unis, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, États-Unis, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University Comprehensive Cancer Center
-
Elyria, Ohio, États-Unis, 44035
- Mercy Cancer Center-Elyria
-
Independence, Ohio, États-Unis, 44131
- Cleveland Clinic Cancer Center Independence
-
Mansfield, Ohio, États-Unis, 44903
- OhioHealth Mansfield Hospital
-
Mayfield Heights, Ohio, États-Unis, 44124
- Hillcrest Hospital Cancer Center
-
Medina, Ohio, États-Unis, 44256
- Summa Health Medina Medical Center
-
Mentor, Ohio, États-Unis, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, États-Unis, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Parma, Ohio, États-Unis, 44129
- University Hospitals Parma Medical Center
-
Portsmouth, Ohio, États-Unis, 45662
- Southern Ohio Medical Center
-
Ravenna, Ohio, États-Unis, 44266
- University Hospitals Portage Medical Center
-
Sandusky, Ohio, États-Unis, 44870
- North Coast Cancer Care
-
Sandusky, Ohio, États-Unis, 44870
- UH Seidman Cancer Center at Firelands Regional Medical Center
-
Strongsville, Ohio, États-Unis, 44136
- Cleveland Clinic Cancer Center Strongsville
-
West Chester, Ohio, États-Unis, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, États-Unis, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, États-Unis, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, États-Unis, 97015
- Clackamas Radiation Oncology Center
-
Portland, Oregon, États-Unis, 97213
- Providence Portland Medical Center
-
Portland, Oregon, États-Unis, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, États-Unis, 18104
- Saint Luke's Cancer Center - Allentown
-
Altoona, Pennsylvania, États-Unis, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, États-Unis, 15009
- UPMC-Heritage Valley Health System Beaver
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Carlisle, Pennsylvania, États-Unis, 17015
- Carlisle Regional Cancer Center
-
East Stroudsburg, Pennsylvania, États-Unis, 18301
- Pocono Medical Center
-
Easton, Pennsylvania, États-Unis, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, États-Unis, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, États-Unis, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, États-Unis, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, États-Unis, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, États-Unis, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Indiana, Pennsylvania, États-Unis, 15701
- IRMC Cancer Center
-
Johnstown, Pennsylvania, États-Unis, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport, Pennsylvania, États-Unis, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, États-Unis, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, États-Unis, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, États-Unis, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Natrona Heights, Pennsylvania, États-Unis, 15065
- UPMC Cancer Center-Natrona Heights
-
New Castle, Pennsylvania, États-Unis, 16105
- UPMC Jameson
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, États-Unis, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, États-Unis, 15236
- UPMC Jefferson Regional Radiation Oncology
-
Pittsburgh, Pennsylvania, États-Unis, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Quakertown, Pennsylvania, États-Unis, 18951
- Saint Luke's Hospital - Upper Bucks Campus
-
Seneca, Pennsylvania, États-Unis, 16346
- UPMC Cancer Center at UPMC Northwest
-
Stroudsburg, Pennsylvania, États-Unis, 18360
- Saint Luke's Hospital - Monroe Campus
-
Uniontown, Pennsylvania, États-Unis, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, États-Unis, 15301
- UPMC Washington Hospital Radiation Oncology
-
West Reading, Pennsylvania, États-Unis, 19611
- Reading Hospital
-
Wexford, Pennsylvania, États-Unis, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Anderson, South Carolina, États-Unis, 29621
- AnMed Health Cancer Center
-
Bluffton, South Carolina, États-Unis, 29910
- Saint Joseph's/Candler - Bluffton Campus
-
Boiling Springs, South Carolina, États-Unis, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, États-Unis, 29615
- Prisma Health Cancer Institute - Eastside
-
Greer, South Carolina, États-Unis, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, États-Unis, 29651
- Gibbs Cancer Center-Pelham
-
Rock Hill, South Carolina, États-Unis, 29730
- Rock Hill Radiation Therapy Center
-
Seneca, South Carolina, États-Unis, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, États-Unis, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Conroe, Texas, États-Unis, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Galveston, Texas, États-Unis, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, États-Unis, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, États-Unis, 77079
- UT MD Anderson - West Houston
-
League City, Texas, États-Unis, 77573
- UTMB Cancer Center at Victory Lakes
-
League City, Texas, États-Unis, 77573
- UT MD Anderson - League City
-
Lubbock, Texas, États-Unis, 79410
- Covenant Medical Center-Lakeside
-
Sugar Land, Texas, États-Unis, 77478
- UT MD Anderson - Sugar Land
-
-
Utah
-
Murray, Utah, États-Unis, 84107
- Intermountain Medical Center
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, États-Unis, 84106
- Utah Cancer Specialists-Salt Lake City
-
St. George, Utah, États-Unis, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Saint Johnsbury, Vermont, États-Unis, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Falls Church, Virginia, États-Unis, 22042
- Inova Fairfax Hospital
-
Hampton, Virginia, États-Unis, 23666
- Sentara Cancer Institute at Sentara CarePlex Hospital
-
Norfolk, Virginia, États-Unis, 23507
- Sentara Norfolk General Hospital
-
Richmond, Virginia, États-Unis, 23298
- VCU Massey Comprehensive Cancer Center
-
Virginia Beach, Virginia, États-Unis, 23454
- Sentara Virginia Beach General Hospital
-
-
Washington
-
Federal Way, Washington, États-Unis, 98003
- Saint Francis Hospital
-
Kennewick, Washington, États-Unis, 99336
- Tri-Cities Cancer Center
-
Longview, Washington, États-Unis, 98632
- PeaceHealth Saint John Medical Center
-
Mount Vernon, Washington, États-Unis, 98274
- Skagit Regional Health Cancer Care Center
-
Seattle, Washington, États-Unis, 98195
- University of Washington Medical Center - Montlake
-
Spokane, Washington, États-Unis, 99208
- Spokane Valley Cancer Center-Mayfair
-
Spokane, Washington, États-Unis, 99216
- Spokane Valley Cancer Center-Mission
-
Wenatchee, Washington, États-Unis, 98801
- Wenatchee Valley Hospital and Clinics
-
-
West Virginia
-
Morgantown, West Virginia, États-Unis, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, États-Unis, 26101
- Camden Clark Medical Center
-
Wheeling, West Virginia, États-Unis, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Antigo, Wisconsin, États-Unis, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Green Bay, Wisconsin, États-Unis, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, États-Unis, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Johnson Creek, Wisconsin, États-Unis, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, États-Unis, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, États-Unis, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, États-Unis, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, États-Unis, 54143
- Bay Area Medical Center
-
Marshfield, Wisconsin, États-Unis, 54449
- Marshfield Medical Center
-
Menomonee Falls, Wisconsin, États-Unis, 53051
- Froedtert Menomonee Falls Hospital
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, États-Unis, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, États-Unis, 54017
- Cancer Center of Western Wisconsin
-
Oak Creek, Wisconsin, États-Unis, 53154
- Drexel Town Square Health Center
-
Rhinelander, Wisconsin, États-Unis, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Stevens Point, Wisconsin, États-Unis, 54481
- Aspirus Cancer Care - Stevens Point
-
Sturgeon Bay, Wisconsin, États-Unis, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Wausau, Wisconsin, États-Unis, 54401
- Aspirus Cancer Care-Wausau
-
West Bend, Wisconsin, États-Unis, 53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Wisconsin Rapids, Wisconsin, États-Unis, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
PHASE II INCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020)
-
Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx
-
Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
-
Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink)
-
Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup:
- General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration;
- Examination by an ear nose throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation
- Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave
- Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
-
Zubrod performance status of 0-1 within 14 days prior to registration
-
Age >= 18
-
Absolute granulocyte count (AGC) >= 1,500 cells/mm^3 (obtained within 14 days prior to registration on study)
-
Platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to registration on study)
-
Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
-
Total bilirubin < 2 x institutional upper limit of normal (ULN) within 14 days prior to registration
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registration
-
Serum creatinine institutional ULN within 14 days prior to registration or; creatinine clearance (CC) >= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula
-
Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential
-
The following assessments are required within 14 days prior to registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; Note: patients with an initial magnesium < 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator's discretion
-
Patients with feeding tubes are eligible for the study
-
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control
-
Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis
-
PHASE III: Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx
-
PHASE III: Patients with oropharyngeal cancer must have p16-negative based on central review prior to Step 2 registration. All patients with oropharyngeal primary must consent for mandatory tissue submission for central p16 confirmation
-
PHASE III: Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration
- Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection. The gross total resection has to be done within 63 days prior to registration. If, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
-
PHASE III: Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink or tumor in a final separately submitted margin)
-
PHASE III: Pathologic stage III or IV HNSCC (American Joint Committee on Cancer [AJCC] 7th edition), including no distant metastases, based upon the following minimum diagnostic workup:
- General history and physical examination by a radiation oncologist or medical oncologist within 84 days prior to registration;
- Examination by an ENT or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror or fiberoptic or direct procedure), if appropriate, is recommended but not required. Intra-operative examination is acceptable documentation.
- Pre-op Imaging of the head and neck: A neck CT (with contrast and of diagnostic quality) or PET/CT (with contrast and of diagnostic quality) and/or an MRI of the neck of diagnostic quality (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in DICOM format via TRIAD. The report is to be uploaded into Rave.
- Chest CT scan (with or without contrast) or PET/CT that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: If the PET/CT with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
-
PHASE III: Zubrod performance status of 0-1 within 14 days prior to registration
-
PHASE III: Age >= 18
-
PHASE III: Leukocytes >= 2,500 cells/mm^3 (obtained within 14 days prior to registration on study)
-
PHASE III: Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 14 days prior to registration on study)
-
PHASE III: Platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to registration on study)
-
PHASE III: Hemoglobin >= 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable) (obtained within 14 days prior to registration on study)
-
PHASE III: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x institutional ULN may be enrolled) (within 14 days prior to registration)
-
PHASE III: AST or ALT =< 3 x institutional ULN (within 14 days prior to registration)
-
PHASE III: Alkaline phosphatase =< 2.5 x institutional ULN (within 14 days prior to registration)
-
PHASE III: Creatinine clearance (CrCl) >= 50 mL/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula
-
PHASE III: Patients with feeding tubes are eligible for the study
-
PHASE III: Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential
-
PHASE III: All patients must provide study specific informed consent prior to study entry
-
PHASE III: Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:
- A stable regimen of highly active anti-retroviral therapy (HAART);
- No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections;
- A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Exclusion Criteria:
-
PHASE II EXCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020)
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years); noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago
-
Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible
-
Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Severe, active co-morbidity, defined as follows:
-
Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration
-
Transmural myocardial infarction within 6 months prior to registration
-
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
-
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration
-
Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients.
-
-
Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 4):
-
Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels
-
Glucose < 40 mg/dl (< 2.2 mmol/L) or > 250 mg/dl (> 14 mmol/L)
-
Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
-
Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels
-
Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels
-
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
-
Prior allergic reaction to cetuximab
-
PHASE III: Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) with the following exceptions: T1-2, N0, M0 resected differentiated thyroid carcinoma; Note that noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated < 3 years ago
-
PHASE III: Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible
-
PHASE III: Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy (such as anti-EGF therapy), or immune therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, a prior anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is not permitted
-
PHASE III: Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
PHASE III: Severe, active co-morbidity, defined as follows:
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this trial, patients should be class 2B or better within 6 months prior to registration
-
Transmural myocardial infarction within 6 months prior to registration;
-
Severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia;
-
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible.
-
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;
-
History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in a prior radiation field (fibrosis) is permitted, provided that field does not overlap with the planned radiation field for the study cancer;
-
Patients with active tuberculosis (TB) are excluded;
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease;
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
-
History of allogeneic bone marrow transplantation or solid organ transplantation.
-
A diagnosis of immunodeficiency:
- Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note: HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
-
Is receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to registration.
- Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.
- Note: The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- Patients with a history of autoimmune hypothyroidism who are asymptomatic and/or are on a stable dose of thyroid replacement hormone are eligible.
- Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible.
- Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
PHASE III: Grade 3-4 electrolyte abnormalities (CTCAE, v. 4) within 14 days prior to registration:
- Serum calcium (ionized or adjusted for albumin) < 7 mg/dL (1.75 mmol/L) or > 12.5 mg/dL (> 3.1 mmol/L) despite intervention to normalize levels;
- Glucose < 40 mg/dL (< 2.2 mmol/L) or > 250 mg/dL (> 14 mmol/L);
- Magnesium < 0.9 mg/dL (< 0.4 mmol/L) or > 3 mg/dL (> 1.23 mmol/L) despite intervention to normalize levels;
- Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels;
- Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels.
-
PHASE III: Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for up to 5 months from last study treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding and unwilling to discontinue are also excluded
-
PHASE III: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
PHASE III: Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other non-oncologic reasons (e.g., osteoporosis) is allowed
-
PHASE III: Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) for non-oncologic reasons who cannot discontinue it before registration
-
PHASE III: Patients with known distant metastatic disease are excluded
-
PHASE III: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
-
PHASE III: Major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study
-
PHASE III: Administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab.
- Influenza vaccination should be given during influenza season only (approximately October to
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1 (IMRT, cisplatin)
Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study. |
Given IV
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Undergo biopsy
Autres noms:
Undergo collection of blood
Autres noms:
Undergo IMRT
Autres noms:
Ancillary studies |
|
Expérimental: Arm 2 (IMRT, docetaxel)
Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and/or MRI, and collection of blood during follow-up. (CLOSED AS OF 20-MAR-2020) |
Given IV
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Undergo collection of blood
Autres noms:
Undergo IMRT
Autres noms:
Ancillary studies |
|
Expérimental: Arm 3 (IMRT, docetaxel, cetuximab)
Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study. |
Given IV
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Undergo biopsy
Autres noms:
Undergo collection of blood
Autres noms:
Undergo IMRT
Autres noms:
Given IV
Autres noms:
Ancillary studies |
|
Expérimental: Arm 4 (IMRT, cisplatin, atezolizumab)
Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study. |
Given IV
Autres noms:
Undergo CT
Autres noms:
Undergo MRI
Autres noms:
Undergo biopsy
Autres noms:
Undergo collection of blood
Autres noms:
Given IV
Autres noms:
Undergo IMRT
Autres noms:
Ancillary studies |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease-free survival (Phase II)
Délai: From date of randomization until date of local-regional recurrence, distant metastasis or death due to any cause, assessed up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test. |
From date of randomization until date of local-regional recurrence, distant metastasis or death due to any cause, assessed up to 7 years
|
|
Overall survival (Phase III)
Délai: From date of randomization to death due to any cause, assessed up to 7 years
|
Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test. Multivariate analysis will be performed using the Cox proportional hazards model. |
From date of randomization to death due to any cause, assessed up to 7 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Local-regional failure
Délai: From date of randomization until date of local-regional recurrence, assessed up to 7 years
|
The cumulative incidence method will be used to estimate rates, and the failure rates for the experimental arms will be compared against the control using a failure-specific log rank test. |
From date of randomization until date of local-regional recurrence, assessed up to 7 years
|
|
Distant metastasis
Délai: From date of randomization to date of distant metastasis, assessed up to 7 years
|
The cumulative incidence method will be used to estimate rates, and the failure rates for the experimental arms will be compared against the control using a failure-specific log rank test. |
From date of randomization to date of distant metastasis, assessed up to 7 years
|
|
Toxicity
Délai: From start of treatment to death or last follow-up
|
Adverse events will be graded using Common Terminology Criteria for Adverse Events version 4.0. Rates of grade 3+ adverse events overall will be compared between arms by Chi-square test, or Fisher's exact test. |
From start of treatment to death or last follow-up
|
|
Patient-reported outcome, symptom burden
Délai: Time from randomization to a first recovery within at least one MID unit of total symptom severity compared to the baseline (reference) score
|
Time to recovery of baseline total symptom severity from the MD Anderson Symptom Inventory - Head and Neck. The cumulative incidence method will be used to estimate the event rates, and the event rates between arms will be compared using a cause-specific log rank test. The Fine-Gray subdistribution hazards model may be applied to further explore outcomes by treatment arm and other covariates. |
Time from randomization to a first recovery within at least one MID unit of total symptom severity compared to the baseline (reference) score
|
|
Quality of life
Délai: Baseline and 1 year post radiation therapy
|
Quality of life change from baseline at 1-year post RT, as measured by the Functional Assessment of Cancer Therapy - Head and Neck (FACT) Trial Outcome Index (TOI). FACT TOI is a validated efficient summary index of physical/functional outcomes, and disease site-specific items, which is highly reliable and sensitive to change in performance status rating. A constrained longitudinal data analysis model will be fitted with all the time points (discrete), the treatment factor and its interaction. The secondary non-inferiority patient-reported outcome hypothesis will be tested using a confidence interval approach. |
Baseline and 1 year post radiation therapy
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Paul M Harari, NRG Oncology
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Carcinome
- Carcinome épidermoïde
- Carcinome épidermoïde de la tête et du cou
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Techniques cytologiques
- Cytodiagnostic
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Taxes
- Cyclodécanes
- Diterpènes
- Éléments
- Métaux
- Techniques de diagnostic, chirurgicale
- Techniques de chimie, analytique
- Analyse du spectre
- Métaux, lourds
- Composés en platine
- Radiothérapie
- Éléments de transition
- Radiothérapie, conforme
- Radiothérapie, assistée par ordinateur
- Docétaxel
- Cétuximab
- Cisplatine
- Citrate de 1,2-diaminocyclohexaneplatine II
- Biopsie
- Manipulation des échantillons
- Spectroscopie de résonance magnétique
- Platine
- atézolizumab
- Radiothérapie, intensité modulée
- (225) AC-DOTA-C (RGDYK)
Autres numéros d'identification d'étude
- NCI-2013-00500
- U10CA180868 (Subvention/contrat des NIH des États-Unis)
- U10CA021661 (Subvention/contrat des NIH des États-Unis)
- NCI-2013-00500 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- RTOG-1216 (Autre identifiant: CTEP)
- RTOG-1216 (Autre identifiant: NRG Oncology)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .